Prevail Therapeutics is applying precision medicine to the development of gene therapies to slow or stop disease progression in patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics and the transformative success of AAV-based gene therapy to achieve this goal. learn more

At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases.

At Prevail, we focus on two methods of drug administration, based on the disease type: Intra-cisterna magna and intravenous infusion (IV).

Patients interested in learning more may visit our patients page or email [email protected] for more information. Supporting Publications: PR001 Gene therapy for Parkinson’s disease associated with GBA1 mutations

Dec 15, 2020 · Prevail Therapeutics Pipeline PR001 is being developed as a potentially disease-modifying, single-dose AAV9-based gene therapy for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD), delivered by intra-cisterna magna injection.

At Prevail Therapeutics, we are working together to develop and deliver innovative therapies that slow or stop the progression of neurodegenerative disorders, such as Parkinson's disease. Our mission is to translate breakthrough advances in human genetics and gene therapy technology into life-changing medicines for patients.

Address. Prevail Therapeutics 430 East 29th Street, Suite 1520 New York, NY 10016

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an ...

May 9, 2022 · People living with GD1 are at a higher risk of developing Parkinson’s disease because of the genetic connection between both diseases. At Prevail, we are conducting research in Gaucher disease, which has led to our previously initiated PROVIDE trial for patients with GD2.

Prevail Therapeutics is committed to developing safe and effective gene therapies for people living with neurodegenerative conditions worldwide. Recognizing the significant unmet needs in the disease communities we serve, our aim is to make approved therapies widely available as quickly as possible following a rigorous, standardized clinical ...